ExpreS2ion Biotech Holding AB (5JD0)

Overview

ExpreS2ion Biotech Holding AB (publ), along with its subsidiary, ExpreS2ion Biotechnologies ApS, specializes in the development and production of complex proteins for vaccines and diagnostics based in Denmark. Since its inception in 2015, the company has been at the forefront of developing innovative health solutions, including vaccines for COVID-19, influenza, breast cancer, and malaria. It stands out for its proprietary ExpreS2 platform technology, which is licensed to various research institutes and pharmaceutical companies globally. Additionally, ExpreS2ion Biotech offers test kits and reagents, leveraging its technology for research or diagnostics purposes. Collaborating with key industry players like Evaxion Biotech A/S, it is also developing promising vaccine candidates against cytomegalovirus (CMV). The company maintains an online presence through its store, catering to a global clientele from its headquarters in Helsingborg, Sweden.

Products and Services

• Capsid Virus-Like Particle COVID-19 Vaccine

A flagship product currently in Phase III clinical trial, designed to provide protection against the novel coronavirus through advanced capsid virus-like particle technology. This vaccine candidate exemplifies the company's commitment to addressing urgent global health challenges.

• Influenza Vaccine

In development, this vaccine aims to offer a more effective response against seasonal and pandemic influenza strains, leveraging the ExpreS2 platform's ability to produce high-fidelity, complex proteins essential for triggering a robust immune response.

• Breast Cancer Vaccine

Another groundbreaking venture into the use of protein-based vaccines for therapeutic purposes, targeting breast cancer. Still under development, it reflects ExpreS2ion Biotech's involvement in cancer research and its potential contribution to oncology.

• Malaria Vaccine

Aiming at one of the world's most significant health threats, this vaccine candidate is part of ExpreS2ion Biotech's portfolio to combat malaria with innovative biotechnological tools.

• ExpreS2 Platform Licensing

An essential part of the company's service offering, the ExpreS2 platform is made available for licensing to research institutes and pharmaceutical entities. It provides a robust system for the expression of complex proteins, essential for vaccine and diagnostic development processes.

• ExpreS2 Test Kits and Reagents

Expanding its reach into diagnostics, ExpreS2ion Biotech develops and sells test kits and reagents. These are designed to support research and diagnostics, utilizing the proprietary technology of the ExpreS2 platform to facilitate the study of various diseases.